EUVIMEDEUVIMED entdecken
Crossref

Expression levels of matrix metalloproteinases in ascites of patients with ovarian cancer and the relationship with pathological characteristics of ovarian cancer

Shuna S, Ping L, Junfei W

Discussion of Clinical Cases · 10.06.2019 · 6 (2) · 12

DOI: 10.5430/dcc.v6n2p12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discussion of Clinical Cases, online erschienen am 10.06.2019. Verfasst von Shuna S und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the expression levels of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in ascites in ovarian tumor and provide a theoretical basis for the diagnosis and prognosis evaluation of ovarian cancer ascites.

Methods

ELISA was used to detect the levels of MMP-2 and MMP-9 in ascites samples from 73 cases of patients with malignant ovarian tumor, and RIA was used to detect the expression level of CA125 in the serum in these patients.

Results

The expression levels of MMP-2 and MMP-9 in ascites in malignant ovarian tumor were higher than those in ascites in benign ovarian tumor (t = 8.08, 10.39, p < .01), and the difference was of statistical significance. The expression levels of MMP-2 and MMP-9 in patients with stage III and IV malignant ovarian tumors were higher than those in patients with stage I and II malignant ovarian tumors, and the difference was statistically significant (t = 2.75, 2.75, p < .05). There was no statistically significant difference in the expression levels of MMP-2 and MMP-9 among the patients with different pathological types, different histological grades, lymph node metastasis or not, different ascites volumes and different residual lesions (p > .05). The sensitivities of detecting MMP-2 and MMP-9 in ascites were 76.0% and 88.0%, respectively, which were significantly higher than those of ascites cytological examinations (χ2 = 4.61, 12.74, p < .05), but in comparison with serum CA125, there was no statistically significant difference (p > .05). The specificities of detecting MMP-2 and MMP-9 in ascites were 78.3% and 82.6%, respectively, which were significantly lower than those of ascites cytological examinations (χ2 = 5.61, 4.38, p < .05), but in comparison with serum CA125, there was no statistically significant difference (χ2 = 1.64, 2.68, p < .05).

Conclusions

The levels of MMP-2 and MMP-9 in ascites may be markers for the differential diagnosis of benign and malignant ovarian lesions, and they are related to the prognosis in patients with malignant ovarian tumors.

Zitieren

APA

S, S., L, P., & W, J. (2019). Expression levels of matrix metalloproteinases in ascites of patients with ovarian cancer and the relationship with pathological characteristics of ovarian cancer. Discussion of Clinical Cases, 6(2), 12. https://doi.org/10.5430/dcc.v6n2p12

Vancouver

S S, L P, W J. Expression levels of matrix metalloproteinases in ascites of patients with ovarian cancer and the relationship with pathological characteristics of ovarian cancer. Discussion of Clinical Cases. 2019;6(2):12. doi:10.5430/dcc.v6n2p12

BibTeX
@article{S2019,
  author = {S, Shuna and L, Ping and W, Junfei},
  title = {Expression levels of matrix metalloproteinases in ascites of patients with ovarian cancer and the relationship with pathological characteristics of ovarian cancer},
  journal = {Discussion of Clinical Cases},
  year = {2019},
  volume = {6},
  number = {2},
  pages = {12},
  doi = {10.5430/dcc.v6n2p12}
}
Kostenlos starten →